[go: up one dir, main page]

ES2175798T3 - Cd8 como un inhibidor del sistema inmunitario celular. - Google Patents

Cd8 como un inhibidor del sistema inmunitario celular.

Info

Publication number
ES2175798T3
ES2175798T3 ES98950218T ES98950218T ES2175798T3 ES 2175798 T3 ES2175798 T3 ES 2175798T3 ES 98950218 T ES98950218 T ES 98950218T ES 98950218 T ES98950218 T ES 98950218T ES 2175798 T3 ES2175798 T3 ES 2175798T3
Authority
ES
Spain
Prior art keywords
inhibitor
immune system
cellular immune
medicament
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98950218T
Other languages
English (en)
Inventor
Bent Karsten John Rad Jakobsen
George Fu Gao
Ulrich Conrad Gerth
Andrew Kelvin John Radc Sewell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avidex Ltd
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidex Ltd filed Critical Avidex Ltd
Application granted granted Critical
Publication of ES2175798T3 publication Critical patent/ES2175798T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

El uso de una molécula de CD8 o a soluble que comprende un dominio de inmunoglobulina plegado correctamente, en la fabricación de un medicamento para una terapia inmunosupresora.
ES98950218T 1997-10-28 1998-10-28 Cd8 como un inhibidor del sistema inmunitario celular. Expired - Lifetime ES2175798T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9722779.7A GB9722779D0 (en) 1997-10-28 1997-10-28 Human CD8 as an inhibitor of the cellular immune system

Publications (1)

Publication Number Publication Date
ES2175798T3 true ES2175798T3 (es) 2002-11-16

Family

ID=10821228

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98950218T Expired - Lifetime ES2175798T3 (es) 1997-10-28 1998-10-28 Cd8 como un inhibidor del sistema inmunitario celular.

Country Status (16)

Country Link
US (1) US20070191278A1 (es)
EP (1) EP1024822B1 (es)
JP (1) JP2001521005A (es)
KR (1) KR100585246B1 (es)
CN (1) CN1256147C (es)
AT (1) ATE215833T1 (es)
AU (1) AU752910B2 (es)
CA (1) CA2308463A1 (es)
DE (1) DE69804839T2 (es)
DK (1) DK1024822T3 (es)
ES (1) ES2175798T3 (es)
GB (1) GB9722779D0 (es)
NO (1) NO20002148L (es)
NZ (1) NZ504240A (es)
PT (1) PT1024822E (es)
WO (1) WO1999021576A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929993D0 (en) * 1999-12-17 2000-02-09 Avidex Ltd Substances
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
GB0107628D0 (en) * 2001-03-27 2001-05-16 Avidex Ltd Substances
GB0114533D0 (en) * 2001-06-14 2001-08-08 Avidex Ltd Substances
GB0115071D0 (en) * 2001-06-20 2001-08-15 Avidex Ltd Substances
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
GB2398300A (en) * 2003-02-17 2004-08-18 Isis Innovation Method and compositions for boosting immune response
WO2006012416A2 (en) * 2004-07-20 2006-02-02 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
WO2010033722A2 (en) 2008-09-17 2010-03-25 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2732291B1 (en) 2011-07-11 2017-11-29 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
WO2016149404A1 (en) 2015-03-16 2016-09-22 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
CN109476721B (zh) * 2016-04-04 2022-06-28 英蒂分子公司 Cd8-特异性捕获剂、组合物及使用和制备方法
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
US11719705B2 (en) 2017-06-15 2023-08-08 Indi Molecular, Inc. IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
JPH04506061A (ja) * 1989-03-15 1992-10-22 タイコシンスキー，マーク　エル． Ｃｄ８に基づく製剤
US5601828A (en) * 1989-03-15 1997-02-11 Tkb Associates Limited Partnership CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment
US5645837A (en) * 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same

Also Published As

Publication number Publication date
GB9722779D0 (en) 1997-12-24
KR20010024570A (ko) 2001-03-26
DK1024822T3 (da) 2002-08-05
NO20002148D0 (no) 2000-04-27
AU9637498A (en) 1999-05-17
EP1024822A1 (en) 2000-08-09
US20070191278A1 (en) 2007-08-16
NO20002148L (no) 2000-06-27
AU752910B2 (en) 2002-10-03
KR100585246B1 (ko) 2006-06-01
EP1024822B1 (en) 2002-04-10
DE69804839T2 (de) 2002-10-10
HK1031099A1 (en) 2001-06-01
PT1024822E (pt) 2002-09-30
CN1256147C (zh) 2006-05-17
WO1999021576A1 (en) 1999-05-06
CN1283120A (zh) 2001-02-07
JP2001521005A (ja) 2001-11-06
DE69804839D1 (de) 2002-05-16
CA2308463A1 (en) 1999-05-06
ATE215833T1 (de) 2002-04-15
NZ504240A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
ES2175798T3 (es) Cd8 como un inhibidor del sistema inmunitario celular.
DK1036058T3 (da) Adamantanderivater
DE69808130D1 (de) Adamantan-derivate
BR9816155B1 (pt) imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase, bem como medicamento e uso farmacêutico compreendendo as mesmas.
BR9807843B1 (pt) heterociclos bicìclicos dissubstituìdos, composições farmacêuticas, uso, bem como processos para preparação das referidas composições e dos referidos compostos.
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
AR012673A1 (es) Compuesto de ester de etilenglicol de monohidrobenzoporfirina utiles para terapia fotodinamica, composiciones farmaceuticas y uso de los mismos.
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
AR025163A1 (es) Un procedimiento para preparar olefinas, un sistema catalizador soportado, el uso de un compuesto catalizador del grupo 15 que contiene hafnio y el uso deun sistema catalizador que comprende un compuesto catalizador
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
UY26297A1 (es) Vacuna
BR0010418B1 (pt) microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo.
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
DE59300631D1 (de) Biologisch abbaubare, wässrige Dispersionen.
ES2174489T3 (es) Aminoalquiltrialquilsililcelulosa y un procedimiento para el revestimiento de superficies.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
AR005704A1 (es) Heteroariloxazolidinonas
ITRM910460A0 (it) Valvola di non ritorno per condutture di gas.
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2165020T3 (es) Monohidrato de famciclovir.
AR023389A1 (es) Nuevo uso
ECSP003674A (es) Nuevos compuestos
ES1032219Y (es) Dispositivo de plegado para sillas, mesas o pupitres.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1024822

Country of ref document: ES